EPIZYME
Epizyme is a biopharmaceutical company located in Cambridge, MA, that is focused on researching treatments for blood cancer and tumors. Founded in late 2007, the company has brought together premier academic and industry leaders to rapidly translate the exciting discoveries emerging from epigenetic research into specific programs that will produce important, novel, molecularly targeted drugs of the future.
EPIZYME
Industry:
Biopharma Biotechnology Health Care
Founded:
2007-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.epizyme.com
Total Employee:
101+
Status:
Active
Contact:
1(617)349-0707
Total Funding:
834.08 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon WordPress Content Delivery Network Google Universal Analytics
Current Advisors List
Board_observer
Advisor
2007-01-01
Board_member
Board_member
Board_member
2012-05-01
Board_member
Board_member
Board_member
2019-01-01
Current Employees Featured
Robert Horvitz Scientific Co-Founder @ Epizyme
Scientific Co-Founder
Jeffery Kutok Chief Scientific Officer @ Epizyme
Chief Scientific Officer
2020-04-01
Yi Zhang Scientific Co-Founder @ Epizyme
Scientific Co-Founder
Grant Bogle President & Chief Executive Officer @ Epizyme
President & Chief Executive Officer
2021-08-01
Mark De Rosch Chief Regulatory Officer @ Epizyme
Chief Regulatory Officer
2019-09-01
John Weidenbruch General Counsel @ Epizyme
General Counsel
2017-08-01
Tanja Weber SVP, Business Development & Alliance Management @ Epizyme
SVP, Business Development & Alliance Management
2019-05-01
John Bishop SVP, Pharmaceutical Sciences @ Epizyme
SVP, Pharmaceutical Sciences
2017-05-01
Jerald Korn Chief Operating Officer @ Epizyme
Chief Operating Officer
2022-03-01
Erin Boyer Chief People & Culture Officer @ Epizyme
Chief People & Culture Officer
2020-11-01
Founder
Stock Details
Investors List
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Post-IPO Equity - Epizyme
Royalty Pharma
Royalty Pharma investment in Post-IPO Equity - Epizyme
Celgene
Celgene investment in Post-IPO Equity - Epizyme
GlaxoSmithKline
GlaxoSmithKline investment in Venture Round - Epizyme
Leukemia & Lymphoma Society
Leukemia & Lymphoma Society investment in Venture Round - Epizyme
Multiple Myeloma Research Foundation
Multiple Myeloma Research Foundation investment in Grant - Epizyme
New Enterprise Associates
New Enterprise Associates investment in Series B - Epizyme
Kleiner Perkins
Kleiner Perkins investment in Series B - Epizyme
Astellas Venture Management
Astellas Venture Management investment in Series B - Epizyme
Amgen Ventures
Amgen Ventures investment in Series B - Epizyme
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-15 | Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update |
| 2021-08-09 | Epizyme Announces CEO Succession |
| 2020-03-23 | Epizyme Names Infinity’s Jeffery Kutok as Chief Scientific Officer |
Official Site Inspections
http://www.epizyme.com Semrush global rank: 7.1 M Semrush visits lastest month: 594
- Host name: a4ec4c6ea1c92e2e6.awsglobalaccelerator.com
- IP address: 15.197.142.173
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Epizyme"
Epizyme - Crunchbase Company Profile & Funding
Epizyme is a biopharmaceutical company located in Cambridge, MA, that is focused on researching treatments for blood cancer and tumors. Founded in …See details»
Epizyme, Inc. Company Profile | Cambridge, MA - Dun & Bradstreet
Company Description: Epizyme is a commercial-stage biopharmaceutical company that is committed to rewriting treatment for people with cancer and other serious diseases through …See details»
Ipsen completes acquisition of Epizyme expanding its …
PARIS, FRANCE, 12 August 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme).Pursuant to the transaction, Ipsen acquires …See details»
Ipsen to acquire Epizyme, expanding its portfolio in …
Jun 27, 2022 Transaction focused on lead asset Tazverik ® (tazemetostat), a first-in-class EZH2 a inhibitor approved in the U.S.; Acquisition to bolster Ipsen’s growing oncology presence and leverage its infrastructure; Ipsen to …See details»
Epizyme Information - RocketReach
Epizyme now operates as an Ipsen company with a shared goal of delivering innovative treatment options to underserved patients. Ipsen is a global specialty-driven biopharmaceutical group …See details»
Epizyme - Products, Competitors, Financials, Employees, …
Epizyme (NASDAQ: EPZM) is a biopharmaceutical company rewriting treatment for cancer and other serious diseases through epigenetic medicines. It broadly develops its lead product …See details»
Epizyme Inc - AnnualReports.com
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. Its proprietary product platform creates small molecule inhibitors of a 96-member class of enzymes known as …See details»
Epizyme - businessabc
Feb 25, 2025 Epizyme was founded in 2007 by three leading pioneers in epigenetics research – Troy Australia, Gregory Verdeil, and Craig Thompson. The core team consists of leading …See details»
Epizyme Company Profile - Office Locations, Competitors ... - Craft
Aug 4, 2022 Epizyme has 5 employees at their 1 location and $37.43 m in annual revenue in FY 2021. See insights on Epizyme including office locations, competitors, revenue, financials, …See details»
Epizyme - Funding, Financials, Valuation & Investors - Crunchbase
Epizyme is registered under the ticker NASDAQ:EPZM . Their stock opened with $15.00 in its May 31, 2013 IPO. Stock Symbol NASDAQ:EPZM ; Valuation at IPO $400M; Money Raised at …See details»
Epizyme, Inc. Company Profile & Data: stocks, market cap, …
Aug 1, 2022 Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other …See details»
Epizyme Inc Company Profile - Epizyme Inc Overview - GlobalData
Up-to-date Epizyme Inc company overview including funding information, company profile, key statistics, peer comparison and more.See details»
Epizyme 2025 Company Profile: Valuation, Investors, Acquisition
Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing, and …See details»
Epizyme - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 22, 2025 Epizyme has raised a total funding of $51.5M over 6 rounds. Its first funding round was on Oct 07, 2009. Its latest funding round was a Post IPO round on Nov 05, 2019 for …See details»
EPIZYME, INC.
Dec 31, 2021 Our changes to our commercial strategy and organization, adjustments to our operating plans, including operating expense reductions, prioritization of development …See details»
Epizyme - VentureRadar
" Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel …See details»
Company Epizyme, Inc. Deutsche Boerse AG - MarketScreener.com
Epizyme, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the treatment of people with cancer through the discovery, development, and …See details»
Epizyme - Contacts, Employees, Board Members, Advisors & Alumni
Epizyme is a biopharmaceutical company focusing on treatments for blood cancer and tumors. New. Resources. Advanced Search ... Experience the new Crunchbase, powered by AI . …See details»
Epizyme Company Information - Funding, Investors, and More
Epizyme is a biopharmaceutical company focused on the discovery and development of epigenetic medicines to treat cancer and other disease . Seedtable Score 76 Startups. 3. …See details»
Epizyme Announces Leadership Transition for Finance
Aug 15, 2017 Contact Data Contacts: Cheya Pope, Epizyme, Inc. media@epizyme.com 617-229-7561 Monique Allaire, THRUST IR monique@thrustir.com (617) 895-9511See details»